Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2683

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2683
---
 the Securities Act to register shares
of our common stock or securities convertible into or exchangeable for shares of our common stock issued pursuant to the Incentive Plan
or the ESPP. Any such Form S-8 registration statements will automatically become effective upon filing. Accordingly, shares registered
under such registration statements will be available for sale in the open market. The initial registration statement on Form S-8 is expected
to cover shares of our common stock.

In
the future, we may also issue our securities in connection with investments or acquisitions. The amount of shares of our common stock
issued in connection with an investment or acquisition could constitute a material portion of the then-outstanding shares of our common
stock. Any issuance of additional securities in connection with investments or acquisitions may result in additional dilution to our
stockholders.

We
qualify as an “emerging growth company” as well as a “smaller reporting company” within the meaning of the Securities
Act, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies, this could make
our securities less attractive to investors and may make it more difficult to compare our performance with other public companies.

130

We
qualify as an “emerging growth company” within the meaning of the Section 2(a)(19) of the Securities Act, as modified by
the JOBS Act. As such, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public
companies that are not emerging growth companies for as long as we continue to be an emerging growth company, including, but not limited
to, (i) not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, (ii) reduced
disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (iii) exemptions from the requirements
of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously
approved. As a result, our stockholders may not have access to certain information they may deem important. We will remain an emerging
growth company until the earliest of (i) the last day of the fiscal year in which the market value of our common stock that is held by
non-affiliates exceeds $700.0 million as of the end of that year’s second fiscal quarter, (ii) the last day of the fiscal year
in which we have total annual gross revenue of $1.1 million or more